As a consequence of the transfer of its Jyseleca® business to Alfasigma, the revenues and costs related to Jyseleca® for the full years 2024 and 2023 are presented separately from the results of the ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein ...

Doctors are enrolling patients in a groundbreaking clinical trial aimed at reducing cancer recurrence in patients with ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with KRAS+ non-small cell lung cancer as seen in clinical practice.

Acute Myeloid Leukemia (AML) is a hematological malignancy characterized by the rapid, uncontrolled growth of immature myeloid cells, leading to bone marrow ...

CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...

A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...

Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...

Equities research analysts at StockNews.com began coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a research report issued to clients and investors on Tuesday. The ...

A revolutionary approach to immune therapy has emerged: engineered immune cells that protect healthy tissue without ...

Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, ...